Publications by authors named "T Gonzalez"

Introduction: Globally, the health and quality of life of millions of people are negatively affected by diabetic foot ulcers (DFUs). To treat these chronic wounds, a novel injectable drug for closing DFUs composed of micronized amniotic membrane was developed. This new therapeutic drug for wound repair expands on traditional allograft therapies by allowing extracellular matrix proteins, growth factors, and cytokines to reach wound anatomies in DFUs that are difficult to treat.

View Article and Find Full Text PDF

Individuals with neurofibromatosis type 1 and schwannomatosis (NF) often face difficult reproductive choices when family planning; however, their experiences and the barriers and enablers to reproductive decision-making are poorly understood. The purpose of this study was to explore the opinions and experiences of individuals with NF in Australia and inform the development of practice recommendations and resources. Focus groups with adults with NF were conducted using a semi-structured interview schedule developed by the research team.

View Article and Find Full Text PDF

Targeted reproductive management (TRM), employing automated monitoring devices (AMD), is as an alternative to the blanket adoption of ovulation synchronization protocols (OvSP) for first postpartum artificial insemination (AI) and a means of reducing the use of OvSP for re-AI of non-pregnant cows. We hypothesized that a TRM that relies heavily on AI of cows on AMD-detected estrus increases improves reproductive performance and economic return. Early-postpartum estrus characteristics of multiparous (n = 941) cows were evaluated at 40 and 41 DIM (Herds 1and 2, respectively) and early-postpartum estrus characteristics of primiparous (n = 539) cows were evaluated at 54 and 55 DIM (Herds 1 and 2, respectively).

View Article and Find Full Text PDF
Article Synopsis
  • Since 2017, combining targeted therapies with traditional chemotherapy has led to better outcomes for acute myeloid leukemia (AML) patients.
  • A study of 5,359 AML patients over 20 years used data from the HARMONY Alliance to analyze treatment outcomes during four 5-year periods from 1997 to 2016.
  • Results show significant improvements in 5-year survival rates and reduced 60-day mortality (from 13.0% to 4.7%), even across different genetic risk groups, indicating that the advancements in treatment have positively affected patient outcomes.
View Article and Find Full Text PDF